Description The Guest Editor presents state-of-the-art articles devoted to therapies for treatment of HCV. The novel therapies addressed in this issue
include interferons, viral kinetics and anti-viral resistence, anti-fibrotics, immunotherapeutics, hepatoprotectants and caspace inhibitors,
and cyclosporine analogues, to name a few.